Cargando…
Pamidronate for the treatment of osteoporosis secondary to chronic cholestatic liver disease in Wistar rats
Osteoporosis is a major complication of chronic cholestatic liver disease (CCLD). We evaluated the efficacy of using disodium pamidronate (1.0 mg/kg body weight) for the prevention (Pr) or treatment (Tr) of cholestasis-induced osteoporosis in male Wistar rats: sham-operated (Sham = 12); bile duct-li...
Autores principales: | Pereira, F.A., Mattar, R., Facincani, I., Defino, H.L.A., Ramalho, L.N.Z., Jorgetti, V., Volpon, J.B., de Paula, F.J.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Medicina Tropical
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854229/ https://www.ncbi.nlm.nih.gov/pubmed/22983176 http://dx.doi.org/10.1590/S0100-879X2012007500143 |
Ejemplares similares
-
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment
por: Spirlandeli, Adriano L., et al.
Publicado: (2017) -
Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis
por: Lim, Mie Jin, et al.
Publicado: (2010) -
Letter to the Editor: Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis
por: Marcuzzi, Annalisa, et al.
Publicado: (2011) -
The Author Response: Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis
por: Park, Won
Publicado: (2011) -
Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
por: Yoon, Ji-Hee, et al.
Publicado: (2021)